{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:08:04Z","timestamp":1789553284253,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"GSK","award":["222161"],"award-info":[{"award-number":["222161"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Remission is a key treatment goal associated with improved patient outcomes in systemic lupus erythematosus (SLE), often measured by Definition of Remission In SLE (DORIS) criteria. In a\n                      <jats:italic toggle=\"yes\">post hoc<\/jats:italic>\n                      analysis of clinical trial data, belimumab, a B-cell modulator targeting the central immunopathogenic pathway in SLE, plus standard therapy, improved DORIS remission rates versus placebo plus standard therapy; however, US real-world remission rates remain limited. Measuring DORIS criteria in real-world clinical practice is challenging because required variables, particularly the SLE Disease Activity Index (SLEDAI) component, are often unavailable or incompletely recorded. Therefore, we evaluated an adapted DORIS definition for real-world datasets and examined predictors of remission among US patients initiating belimumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational cohort study analysed data for patients with SLE initiating belimumab from the OM1 PremiOM\u2122 SLE dataset, comprising electronic health records\/healthcare claims data (2013\u20132024) for patients with SLE. The primary outcome was probability of achieving adapted DORIS remission at 28, 48, and 52\u00a0weeks post-treatment initiation, defined as clinician-recorded SLEDAI (crSLEDAI) or estimated SLEDAI (eSLEDAI) = 0, Physician Global Assessment (PGA) &lt;2 on a 0\u201310 numerical rating scale, and prednisone-equivalent dose \u22645\u00a0mg\/day. Kaplan\u2013Meier estimates provided remission probabilities and logistic regression identified predictors of remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most patients (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 398) were White, female, from the Southern region of the USA, and had commercial insurance. The probability of achieving adapted DORIS remission reached 28.3% (95% confidence interval: 19.8\u201335.9) by 52\u00a0weeks post-belimumab initiation. Older patients (\u226550\u00a0years), non-White individuals, and patients with cr\/eSLEDAI \u22645 demonstrated slightly higher remission probabilities than their counterparts; however, estimates differed by censoring approach, and confidence bounds overlapped. Adjusted multivariable analysis confirmed increasing age, non-White race, and cr\/eSLEDAI \u22645 as significant predictors of remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates the application of an adapted DORIS definition to large real-world observational datasets. The probability of adapted DORIS remission in US patients initiating belimumab was similar to rates reported in observational studies outside the USA, supporting the real-world effectiveness of belimumab. The increased likelihood of remission in patients with cr\/eSLEDAI \u22645 supports the benefits of initiating belimumab treatment early in the disease course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033261473961","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:52:36Z","timestamp":1786528356000},"page":"1246-1256","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Achievement of real-world adapted DORIS remission targets among patients with systemic lupus erythematosus initiating belimumab in the USA: A retrospective, observational, cohort study"],"prefix":"10.1177","volume":"35","author":[{"given":"Aarat M.","family":"Patel","sequence":"first","affiliation":[{"name":"GSK"},{"name":"University of Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee L.","family":"Gennarelli","sequence":"additional","affiliation":[{"name":"Cencora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Bello","sequence":"additional","affiliation":[{"name":"Cencora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bonakdar","sequence":"additional","affiliation":[{"name":"Cencora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Worley","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_3_5_4_2","first-page":"85","article-title":"Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care","volume":"32","author":"Castrej\u00f3n I","year":"2014","unstructured":"Castrej\u00f3n I, Tani C, Jolly M, et al. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol 2014; 32: 85\u201395.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25690"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0702-6"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00162-0"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.127"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead696"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074044"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03389-4"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00601-w"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001586"},{"key":"e_1_3_5_18_2","unstructured":"OM1. Systemic lupus erythermatosus: longitudinal multi-source curated registries offering rapid access to deep clinical data insights and outcomes. https:\/\/www.om1.com\/topics\/rheum\/ (2025) Accessed 28 July 2026."},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/190257"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead460"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070367"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24464"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131137"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23720"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22774"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241274911"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211004722"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41900"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209489"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319886028"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24063"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217070"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261473961","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033261473961","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261473961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:46:47Z","timestamp":1789552007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033261473961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/09612033261473961"],"URL":"https:\/\/doi.org\/10.1177\/09612033261473961","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}